Back to Search
Start Over
<scp>CAR‐T</scp> cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance status
- Source :
- American Journal of Hematology. 97:933-941
- Publication Year :
- 2022
- Publisher :
- Wiley, 2022.
-
Abstract
- In this open-label, single-arm, phase I/II clinical trial, we evaluated the efficacy of anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) therapy in 49 relapsed/refractory multiple myeloma (RRMM) patients, including 20 with Eastern Cooperative Oncology Group (ECOG) grade 3-4. After HDS269B infusion (9 × 10
Details
- ISSN :
- 10968652 and 03618609
- Volume :
- 97
- Database :
- OpenAIRE
- Journal :
- American Journal of Hematology
- Accession number :
- edsair.doi.dedup.....9bfe83e1e2988e7907d8614c40c79a7b